EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Reports Financial Results For Second Quarter 2021

29 يوليو 2021 16:05:01 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility

29 يوليو 2021 07:24:59 بحسب Nasdaq GlobeNewswire

Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use

26 يوليو 2021 09:01:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021

15 يوليو 2021 06:30:00 بحسب Nasdaq GlobeNewswire

COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization

11 يونيو 2021 16:35:24 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate

26 مايو 2021 06:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT

06 مايو 2021 06:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

05 مايو 2021 16:05:02 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for First Quarter 2021

29 أبريل 2021 16:05:02 بحسب Nasdaq GlobeNewswire

Statement on Issuance of Form FDA 483 at Emergent Bayview Facility

21 أبريل 2021 12:46:42 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021

15 أبريل 2021 06:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson’s COVID-19 Vaccine

04 أبريل 2021 22:09:06 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19

02 أبريل 2021 08:00:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

01 مارس 2021 06:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020

18 فبراير 2021 16:05:01 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021

04 فبراير 2021 06:30:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

10 يناير 2021 14:00:00 بحسب Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

04 يناير 2021 06:30:00 بحسب Nasdaq GlobeNewswire